Molecular mechanisms of Duchenne muscular dystrophy and new therapeutic strategies

2Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Duchenne muscular dystrophy (DMD) is an X-linked genetic disease affecting approximately 1 in 5,000 born boys. It is caused by mutations in the DMD gene encoding dystrophin, which protects muscle fibers upon contraction. Its absence leads to muscle weakening and premature death mostly due to cardio-respiratory failure. Many experimental therapies have been developed to restore functional dystrophin or coun-teract processes contributing to disease progression. Nonetheless, DMD remains an incurable disease, and glucocorticoids, exerting many side effects, still serve as the “gold standard” of treatment. Hence, there is a need to develop innovative therapeutic options that will at least alleviate the symptoms of DMD. Among them, targeting specific microRNAs (miRs), e.g. miR-378a, restoring normal angiogenesis and the use of cytoprotective factors such as heme oxygenase-1 (HO-1) or hydrogen sulfide (H2 S) might be of special interest. In this review, we describe both the pathology of the disease and the aforementioned new therapeutic options in DMD.

Cite

CITATION STYLE

APA

Podkalicka, P., Myszka, M., Dulak, J., & Łoboda, A. (2022). Molecular mechanisms of Duchenne muscular dystrophy and new therapeutic strategies. Postepy Biochemii, 68(2), 109–122. https://doi.org/10.18388/pb.2021_428

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free